News | October 16, 2025
Syngene International invests in peptide laboratory in Bengaluru
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
Merck will showcase results in innovative solutions in HIV treatment and prevention
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Phase 1 dosing is expected to finish by the end of 2025
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
